IL156280A0 - Crystalline forms of atorvastatin - Google Patents
Crystalline forms of atorvastatinInfo
- Publication number
- IL156280A0 IL156280A0 IL15628001A IL15628001A IL156280A0 IL 156280 A0 IL156280 A0 IL 156280A0 IL 15628001 A IL15628001 A IL 15628001A IL 15628001 A IL15628001 A IL 15628001A IL 156280 A0 IL156280 A0 IL 156280A0
- Authority
- IL
- Israel
- Prior art keywords
- crystalline forms
- atorvastatin
- directed
- present
- forms
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 1
- 229960005370 atorvastatin Drugs 0.000 title 1
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 abstract 1
- 229960001770 atorvastatin calcium Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00811249 | 2000-12-27 | ||
| PCT/EP2001/015012 WO2002051804A1 (en) | 2000-12-27 | 2001-12-19 | Crystalline forms of atorvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL156280A0 true IL156280A0 (en) | 2004-01-04 |
Family
ID=8175112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15628001A IL156280A0 (en) | 2000-12-27 | 2001-12-19 | Crystalline forms of atorvastatin |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7538136B2 (is) |
| EP (2) | EP2000461A1 (is) |
| JP (2) | JP2004516311A (is) |
| KR (1) | KR100790766B1 (is) |
| CN (1) | CN1273449C (is) |
| AT (1) | ATE420070T1 (is) |
| AU (1) | AU2002224952B2 (is) |
| CA (7) | CA2622697A1 (is) |
| CZ (1) | CZ20032019A3 (is) |
| DE (1) | DE60137364D1 (is) |
| ES (1) | ES2319870T3 (is) |
| HR (1) | HRP20030607A2 (is) |
| HU (1) | HUP0302519A3 (is) |
| IL (1) | IL156280A0 (is) |
| IS (1) | IS6859A (is) |
| MX (1) | MXPA03005879A (is) |
| NO (1) | NO20032758D0 (is) |
| NZ (1) | NZ527048A (is) |
| PL (1) | PL365312A1 (is) |
| PT (1) | PT1345896E (is) |
| SK (1) | SK9532003A3 (is) |
| WO (1) | WO2002051804A1 (is) |
| ZA (1) | ZA200304297B (is) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) * | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SK6592003A3 (en) * | 2000-11-03 | 2004-01-08 | Teva Pharma | Atorvastatin hemi-calcium form VII |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CZ20032019A3 (cs) * | 2000-12-27 | 2003-10-15 | Ciba Specialty Chemicals Holding Inc. | Krystalické formy Atorvastatinu |
| IL158790A0 (en) * | 2001-06-29 | 2004-05-12 | Warner Lambert Co | Crystalline forms of [r-(*,r*)]-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| AU2002255479B2 (en) * | 2001-07-30 | 2008-09-11 | Dr. Reddy's Laboratories Ltd. | Crystalline forms VI and VII of atorvastatin clacium |
| US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| CN100430405C (zh) * | 2001-08-16 | 2008-11-05 | 特瓦制药工业有限公司 | 制备他汀类的钙盐形式的方法 |
| EP1572638A4 (en) * | 2001-08-31 | 2010-05-05 | Morepen Lab Ltd | IMPROVED METHOD FOR THE PRODUCTION OF AMORPHIC ATORVASTATIN CALCIUM SALT (2: 1) |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| PL372303A1 (en) * | 2002-02-15 | 2005-07-11 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
| CA2475123A1 (en) | 2002-02-19 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Desolvating solvates of atorvastatin hemi-calcium |
| AU2002330735A1 (en) * | 2002-09-03 | 2004-03-29 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
| EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
| CA2508871C (en) * | 2002-11-28 | 2008-09-09 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| AU2005223491A1 (en) * | 2004-03-17 | 2005-09-29 | Ranbaxy Laboratories Limited | Crystalline form of atorvastatin hemi calcium |
| EP1727795B1 (en) | 2004-03-17 | 2012-02-15 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| JP2007536373A (ja) * | 2004-05-05 | 2007-12-13 | ファイザー・プロダクツ・インク | アトルバスタチンの塩形態 |
| US8435530B2 (en) | 2004-06-11 | 2013-05-07 | Sbi Biotech Co., Ltd. | Methods for suppressing activity of activated interferon-producing cells |
| JP5000502B2 (ja) * | 2004-07-16 | 2012-08-15 | レツク・フアーマシユーテイカルズ・デー・デー | アトルバスタチンカルシウムの酸化分解生成物 |
| BRPI0513422A (pt) | 2004-07-20 | 2008-05-06 | Warner Lambert Co | formas de sais cálcio do ácido (r-(r*))-2-(4- fluorfenil)-(beta), (sigma)-diidróxi-5-(1-metiletil) -3-fenil-4-((fenilamino) carbonil)-1h-pirrol-1-heptanóico (2:1) |
| AU2005298383A1 (en) | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| CA2499047A1 (en) * | 2005-03-01 | 2006-09-01 | Apotex Pharmachem Inc. | Process for producing atorvastatin hemicalcium |
| EA014079B1 (ru) * | 2005-04-08 | 2010-08-30 | Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг | Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина |
| CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
| ATE466840T1 (de) * | 2005-11-21 | 2010-05-15 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium |
| CN101370774A (zh) * | 2005-12-13 | 2009-02-18 | 特瓦制药工业有限公司 | 阿托伐他汀半钙的晶形及其制备方法 |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| JP2008007507A (ja) * | 2006-06-28 | 2008-01-17 | Teva Pharmaceutical Industries Ltd | 結晶形アトルバスタチン |
| WO2009007856A2 (en) * | 2007-07-11 | 2009-01-15 | Actavis Group Ptc Ehf | Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| CN104983702A (zh) * | 2015-07-23 | 2015-10-21 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
| JP2019167295A (ja) * | 2016-07-04 | 2019-10-03 | ゼリア新薬工業株式会社 | １，５−ベンゾジアゼピン化合物カルシウム塩の製造法 |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| SG45369A1 (en) * | 1993-01-19 | 1998-10-16 | Warner Lambert Co | Stable oral ci-981 formulation and process of preparing same |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| CZ294108B6 (cs) * | 1995-07-17 | 2004-10-13 | Warner@Lambertácompany | Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| HRP960312B1 (en) | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| SK286789B6 (sk) * | 1999-11-17 | 2009-05-07 | Teva Pharmaceutical Industries Ltd. | Kryštalická forma atorvastatínu vápenatého alebo jeho hydrátu, spôsob jej prípravy a farmaceutická kompozícia s jej obsahom |
| US7411075B1 (en) * | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| DE60026737T2 (de) | 1999-12-17 | 2006-09-21 | Pfizer Science And Technology Ireland Ltd., Dun Laoghaire | Verfahren zur herstellung von kristallin atorvastin kalcium |
| SK6592003A3 (en) * | 2000-11-03 | 2004-01-08 | Teva Pharma | Atorvastatin hemi-calcium form VII |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CZ20032019A3 (cs) * | 2000-12-27 | 2003-10-15 | Ciba Specialty Chemicals Holding Inc. | Krystalické formy Atorvastatinu |
| WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| IL158790A0 (en) * | 2001-06-29 | 2004-05-12 | Warner Lambert Co | Crystalline forms of [r-(*,r*)]-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| AU2002255479B2 (en) * | 2001-07-30 | 2008-09-11 | Dr. Reddy's Laboratories Ltd. | Crystalline forms VI and VII of atorvastatin clacium |
-
2001
- 2001-12-19 CZ CZ20032019A patent/CZ20032019A3/cs unknown
- 2001-12-19 CA CA002622697A patent/CA2622697A1/en not_active Abandoned
- 2001-12-19 IL IL15628001A patent/IL156280A0/xx not_active IP Right Cessation
- 2001-12-19 HU HU0302519A patent/HUP0302519A3/hu unknown
- 2001-12-19 AU AU2002224952A patent/AU2002224952B2/en not_active Ceased
- 2001-12-19 CA CA002622727A patent/CA2622727A1/en not_active Abandoned
- 2001-12-19 SK SK953-2003A patent/SK9532003A3/sk unknown
- 2001-12-19 MX MXPA03005879A patent/MXPA03005879A/es active IP Right Grant
- 2001-12-19 EP EP08016057A patent/EP2000461A1/en not_active Withdrawn
- 2001-12-19 JP JP2002552901A patent/JP2004516311A/ja not_active Withdrawn
- 2001-12-19 CN CNB018215017A patent/CN1273449C/zh not_active Expired - Fee Related
- 2001-12-19 CA CA002623600A patent/CA2623600A1/en not_active Abandoned
- 2001-12-19 DE DE60137364T patent/DE60137364D1/de not_active Expired - Fee Related
- 2001-12-19 PL PL01365312A patent/PL365312A1/xx not_active Application Discontinuation
- 2001-12-19 AT AT01994809T patent/ATE420070T1/de not_active IP Right Cessation
- 2001-12-19 NZ NZ527048A patent/NZ527048A/xx unknown
- 2001-12-19 CA CA002623599A patent/CA2623599A1/en not_active Abandoned
- 2001-12-19 CA CA002626317A patent/CA2626317A1/en not_active Abandoned
- 2001-12-19 ES ES01994809T patent/ES2319870T3/es not_active Expired - Lifetime
- 2001-12-19 EP EP01994809A patent/EP1345896B1/en not_active Expired - Lifetime
- 2001-12-19 HR HR20030607A patent/HRP20030607A2/hr not_active Application Discontinuation
- 2001-12-19 KR KR1020037008685A patent/KR100790766B1/ko not_active Expired - Fee Related
- 2001-12-19 WO PCT/EP2001/015012 patent/WO2002051804A1/en not_active Ceased
- 2001-12-19 CA CA002622477A patent/CA2622477A1/en not_active Abandoned
- 2001-12-19 CA CA002431068A patent/CA2431068C/en not_active Expired - Fee Related
- 2001-12-19 US US10/130,197 patent/US7538136B2/en not_active Expired - Fee Related
- 2001-12-19 PT PT01994809T patent/PT1345896E/pt unknown
-
2003
- 2003-06-02 ZA ZA200304297A patent/ZA200304297B/en unknown
- 2003-06-17 NO NO20032758A patent/NO20032758D0/no not_active Application Discontinuation
- 2003-06-24 IS IS6859A patent/IS6859A/is unknown
-
2004
- 2004-06-02 US US10/860,084 patent/US20040220255A1/en not_active Abandoned
-
2006
- 2006-05-09 US US11/431,184 patent/US20060205805A1/en not_active Abandoned
-
2009
- 2009-04-17 US US12/386,413 patent/US20090281162A1/en not_active Abandoned
- 2009-05-27 JP JP2009127757A patent/JP2009221216A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL156280A0 (en) | Crystalline forms of atorvastatin | |
| SI1535613T1 (sl) | Postopek za pripravo polimorfne oblike atorvastatin kalcija | |
| DE69915004D1 (de) | 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate | |
| ZA200309887B (en) | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents. | |
| CA2378148A1 (en) | Nematicidal trifluorobutenes | |
| PL353910A1 (en) | Novel compounds 0 derivatives of alpha-amino acid, method of obtaining them and compositions containing such derivatives | |
| WO2003013512A3 (en) | Crystalline forms of fluvastatin sodium | |
| TNSN04024A1 (en) | Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation | |
| AU2001284385A1 (en) | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) | |
| CA2508871A1 (en) | Crystalline form f of atorvastatin hemi-calcium salt | |
| ID28601A (id) | Proses penyiapan senyawa-senyawa 1,4-dihidropiridin | |
| UA66866C2 (uk) | Синтез морфолінових похідних | |
| IL157709A0 (en) | Process for the preparation of 1,2-benzisoxazole-3-acetic acid | |
| CA2213810A1 (en) | Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods | |
| MY129094A (en) | Condensed polycyclic compounds | |
| WO2002053537A8 (en) | Process for preparing (±) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine | |
| WO2003007872A3 (en) | Process for the preparation of citalopram hydrobromide | |
| BRPI0113727B1 (is) | ||
| WO1999040078A3 (en) | Process for the preparation of sotolon | |
| GR20010100123A (el) | Μεθοδος παρασκευης της σιταλοπραμης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |